The GEFH1 antibody targets the Guanine Nucleotide Exchange Factor H1 (GEFH1), also known as ARHGEF2. a protein belonging to the RhoGEF family. GEFH1 regulates Rho GTPases, particularly RhoA and Cdc42. by catalyzing the exchange of GDP for GTP, thereby activating downstream signaling pathways involved in cytoskeletal reorganization, cell migration, and neuronal development. It is highly expressed in the brain, where it influences microtubule dynamics, dendritic spine formation, and synaptic plasticity. Dysregulation of GEFH1 has been linked to neurological disorders, including epilepsy, autism spectrum disorders, and neurodegenerative conditions, as well as cancer progression due to its role in cell cycle control and invasion.
GEFH1 antibodies are widely used in research to detect endogenous GEFH1 protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These tools help elucidate GEFH1’s spatial-temporal expression, interaction partners, and post-translational modifications. Commercial GEFH1 antibodies are typically raised in rabbits or mice, with validation across multiple applications and species specificity (human, mouse, rat). Researchers rely on these antibodies to explore GEFH1’s dual roles in neurodevelopment and disease pathogenesis, particularly its interplay with microtubule-associated proteins and its potential as a therapeutic target. Proper validation, including knockout controls, is critical due to occasional cross-reactivity with related GEF family members.